Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific completes heart failure trial enrolment

Boston Scientific completes heart failure trial enrolment

29th April 2008

Boston Scientific has announced that it has completed enrolment in its multicentre automatic defibrillator implantation trial with cardiac resynchronisation therapy (MADIT-CRT).

In total, 1,820 patients have been registered for the trial which will assess the potential benefits of the company’s cardiac resynchronisation therapy defibrillators (CRT-Ds) in a new heart failure patient population.

The MADIT-CRT study follows the MADIT, MADIT II and Companion studies sponsored by the company’s cardiac rhythm management group.

It will test whether CRT-Ds can slow the progression of heart failure in patients who have survived heart attacks and those who have other forms of impaired heart function.

Arthur Moss, professor of medicine at the University of Rochester, said: “This study builds on the observations made in the Companion trial, which evaluated the benefits of CRT-D therapy in patients with late-stage, symptomatic heart failure.”

He added that, if positive, this study could address questions regarding the potential of resynchronisation defibrillator therapy to affect the clinical progression of heart failure by earlier intervention.

Last week, Boston Scientific announced its financial results for the first quarter of 2008, reporting net sales of $2.046 billion (1.03 billion pounds) during the period.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.